ArticleJournal for immunotherapy of cancer2023
Open access · goldAbstract read
In one paragraph
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
8.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 35 citations in OpenAlex.
- Tumoral and Systemic Immune Correlates of Response to Concurrent Pembrolizumab and Chemoradiotherapy in Patients with Resected High-Risk Head and Neck Squamous Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Patient-derived organoids for personalized drug response profiling and multi-omics integration in oral squamous cell carcinoma.iScience · 2026Article
- β-Adrenergic Signaling Promotes Anti-Tumor Immunity in TP53-mutant Oral Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The multistep progression of areca nut-induced oral cancer: a mechanistic roadmap from pathogenesis to precision therapy.Life medicine · 2026Review
- The Emerging Role of Nanocarrier-Based Delivery Systems for cGAS-STING Activation in Cancer Immunotherapy.International journal of nanomedicine · 2026Review
- Comprehensive Exploration of NOTCH2NLA Across Cancers and Its Potential Roles in Prognosis and Immune System Interactions.Current medicinal chemistry · 2026Article
- De-escalating radiotherapy in pathologic complete response oral cancer after neoadjuvant immunochemotherapy: equal survival, better life, and a biomarker guide.Frontiers in oncology · 2026Article
- CENTRA: knowledge-based gene contextuality graphs reveal functional master regulators by centrality and fractality.NAR genomics and bioinformatics · 2025Article
- Serum from patients with oral squamous cell carcinoma remodels the tumor immune escape ecological niche by promoting regulatory T‑cell differentiation and T‑cell exhaustion.Oncology reports · 2025Article
- Molecular Characteristics and Treatment Implications of TP53 Gain-of-Function Mutations in Non-Small Cell Lung Cancer.Cancer medicine · 2025Article
- Detection of Viruses with Oncogenic and Oncomodulatory Potential in Head and Neck Tumors-External Auricle.Biomedicines · 2025Article
- Molecular and Genetic Pathogenesis of Oral Cancer: A Basis for Customized Diagnosis and Treatment.Biology · 2025Review
- EarlybioRxiv : the preprint server for biology · 2025Article
- Oral squamous cell carcinoma: Insights into cellular heterogeneity, drug resistance, and evolutionary trajectories.Cell biology and toxicology · 2025Review
- The CRISPR-Cas revolution in head and neck cancer: a new era of targeted therapy.Functional & integrative genomics · 2025Review
- Single-cell RNA sequencing reveals a reprogramming of hepatic immune cells and a protective role for B cells in MASH-driven HCC.Hepatology communications · 2025Article
- Article
- ANAPC10 expression predicts poor prognosis in oral squamous cell carcinoma and promotes tumor growth via the PI3K/AKT/mTOR pathway.Discover oncology · 2025Article
- Transcriptome combined with single-cell sequencing explored prognostic markers associated with T cell exhaustion characteristics in head and neck squamous carcinoma.Scientific reports · 2025Article
- Interplay between hypoxia, RNA methylation, and HPV in head and neck squamous cell carcinomas: drivers of oncogenesis and resistance to therapy.EXCLI journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Yewen Shi *Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-5688-267X
Xiaoyong Ren *Department of Otorhinolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Shaolong CaoDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xi ChenDepartment of Otorhinolaryngology-Head and Neck Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Bo YuanDepartment of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fabio Henrique Brasil da CostaDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Alanis E Rodriguez RosarioDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Arnoldo CoronaDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Chieko MichikawaDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ratna VeeramachaneniDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abdullah A OsmanDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tongxin XieDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wenyi WangDepartment of Bioinformatics & Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Andrew G SikoraDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA rrangel@mdanderson.org agsikora@mdanderson.org jmyers@mdanderson.org.
Jeffrey N MyersDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA rrangel@mdanderson.org agsikora@mdanderson.org jmyers@mdanderson.org.
Roberto RangelDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA rrangel@mdanderson.org agsikora@mdanderson.org jmyers@mdanderson.org.ORCID 0000-0002-9088-7957
The University of Texas MD Anderson Cancer Center · USSecond Affiliated Hospital of Xi'an Jiaotong University · CN
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MThe PreVAIL-kIds Common ProtocolR33HD105593 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI ALLEN, CARL E, ANNAPRAGADA, ANANTH V · 2023 to 2023
$6.3MTargeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancerU01DE028233 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANNAPRAGADA, ANANTH V, SIKORA, ANDREW · 2018 to 2022
$3.9MFunctional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancersR01DE030875 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Jeffrey Nicholas Myers, Andrew Sikora · 2022 to 2026
$2.8MStatistical methods for genomic analysis of heterogeneous tumorsR01CA268380 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Wenyi Wang · 2022 to 2026
$2.4MStatistical methods for genomic analysis of heterogeneous tumorsR01CA183793 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, WENYI · 2014 to 2018
$1.7MStatistical methods and tools for cancer risk prediction in families with germline mutations in TP53R01CA239342 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, WENYI · 2019 to 2022
$1.5MNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA183793NCI NIH HHS R01 CA268380NICHD NIH HHS R33 HD105593NIDCR NIH HHS R01 DE030875NIDCR NIH HHS U01 DE028233
Abstract
background
methodsShort hairpin RNA knockdown of mutant
resultsMutant
conclusionsThese findings demonstrate that syngeneic tumors bearing the
Indexed as
Carcinoma, Squamous CellHead and Neck NeoplasmsMouth NeoplasmsTumor MicroenvironmentTumor Suppressor Protein p53AnimalsCD8-Positive T-LymphocytesCytokinesDisease Models, AnimalGain of Function MutationHumansMiceMutationSquamous Cell Carcinoma of Head and NeckCytokinesTP53 protein, humanTumor Suppressor Protein p53cytokineshead and neck neoplasmsimmune checkpoint inhibitorsimmunotherapytumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.